AIMS: This review posits that fatty acid amide hydrolase (FAAH) inhibition has therapeutic potential against neuropathological states including traumatic brain injury; Alzheimer's, Huntington's, and Parkinson's diseases; and stroke. MAIN METHODS: This proposition is supported by data from numerous in vitro and in vivo experiments establishing metabolic and pharmacological contexts for the neuroprotective role of the endogenous cannabinoid ("endocannabinoid") system and selective FAAH inhibitors. KEY FINDINGS: The systems biology of endocannabinoid signaling involves two main cannabinoid receptors, the principal endocannabinoid lipid mediators N-arachidonoylethanolamine ("anandamide") (AEA) and 2-arachidonoyl glycerol (2-AG), related metabolites, and the proteins involved in endocannabinoid biosynthesis, biotransformation, and transit. The endocannabinoid system is capable of activating distinct signaling pathways on-demand in response to pathogenic events or stimuli, thereby enhancing cell survival and promoting tissue repair. Accumulating data suggest that endocannabinoid system modulation at discrete targets is a promising pharmacotherapeutic strategy for treating various medical conditions. In particular, neuronal injury activates cannabinoid signaling in the central nervous system as an intrinsic neuroprotective response. Indirect potentiation of this salutary response through pharmacological inhibition of FAAH, an endocannabinoid-deactivating enzyme, and consequent activation of signaling pathways downstream from cannabinoid receptors have been shown to promote neuronal maintenance and function. SIGNIFICANCE: This therapeutic modality has the potential to offer site- and event-specific neuroprotection under conditions where endocannabinoids are being produced as part of a physiological protective mechanism. In contrast, direct application of cannabinoid receptor agonists to the central nervous system may activate CB receptors indiscriminately and invite unwanted psychotrophic effects. Copyright 2009 Elsevier Inc. All rights reserved.
AIMS: This review posits that fatty acid amide hydrolase (FAAH) inhibition has therapeutic potential against neuropathological states including traumatic brain injury; Alzheimer's, Huntington's, and Parkinson's diseases; and stroke. MAIN METHODS: This proposition is supported by data from numerous in vitro and in vivo experiments establishing metabolic and pharmacological contexts for the neuroprotective role of the endogenous cannabinoid ("endocannabinoid") system and selective FAAH inhibitors. KEY FINDINGS: The systems biology of endocannabinoid signaling involves two main cannabinoid receptors, the principal endocannabinoidlipid mediators N-arachidonoylethanolamine ("anandamide") (AEA) and 2-arachidonoyl glycerol (2-AG), related metabolites, and the proteins involved in endocannabinoid biosynthesis, biotransformation, and transit. The endocannabinoid system is capable of activating distinct signaling pathways on-demand in response to pathogenic events or stimuli, thereby enhancing cell survival and promoting tissue repair. Accumulating data suggest that endocannabinoid system modulation at discrete targets is a promising pharmacotherapeutic strategy for treating various medical conditions. In particular, neuronal injury activates cannabinoid signaling in the central nervous system as an intrinsic neuroprotective response. Indirect potentiation of this salutary response through pharmacological inhibition of FAAH, an endocannabinoid-deactivating enzyme, and consequent activation of signaling pathways downstream from cannabinoid receptors have been shown to promote neuronal maintenance and function. SIGNIFICANCE: This therapeutic modality has the potential to offer site- and event-specific neuroprotection under conditions where endocannabinoids are being produced as part of a physiological protective mechanism. In contrast, direct application of cannabinoid receptor agonists to the central nervous system may activate CB receptors indiscriminately and invite unwanted psychotrophic effects. Copyright 2009 Elsevier Inc. All rights reserved.
Authors: Zuzana Justinova; Regina A Mangieri; Marco Bortolato; Svetlana I Chefer; Alexey G Mukhin; Jason R Clapper; Alvin R King; Godfrey H Redhi; Sevil Yasar; Daniele Piomelli; Steven R Goldberg Journal: Biol Psychiatry Date: 2008-09-23 Impact factor: 13.382
Authors: Markus Schomacher; Harald D Müller; Clemens Sommer; Stefan Schwab; Wolf-Rüdiger Schäbitz Journal: Brain Res Date: 2008-09-18 Impact factor: 3.252
Authors: JodiAnne T Wood; John S Williams; Lakshmipathi Pandarinathan; Amber Courville; Melissa R Keplinger; David R Janero; Paul Vouros; Alexandros Makriyannis; Carol J Lammi-Keefe Journal: Clin Chem Lab Med Date: 2008 Impact factor: 3.694
Authors: Heather S Hoover; Jacqueline L Blankman; Sherry Niessen; Benjamin F Cravatt Journal: Bioorg Med Chem Lett Date: 2008-07-02 Impact factor: 2.823
Authors: Ying Pei; Richard W Mercier; Jenine K Anday; Ganesh A Thakur; Alexander M Zvonok; Dow Hurst; Patricia H Reggio; David R Janero; Alexandros Makriyannis Journal: Chem Biol Date: 2008-11-24
Authors: Matthew P Gillum; Dongyan Zhang; Xian-Man Zhang; Derek M Erion; Rachel A Jamison; Cheolsoo Choi; Jianying Dong; Marya Shanabrough; Hillary R Duenas; David W Frederick; Jennifer J Hsiao; Tamas L Horvath; Chun Min Lo; Pat Tso; Gary W Cline; Gerald I Shulman Journal: Cell Date: 2008-11-28 Impact factor: 41.582
Authors: Vinogran Naidoo; David A Karanian; Subramanian K Vadivel; Johnathan R Locklear; JodiAnne T Wood; Mahmoud Nasr; Pamela Marie P Quizon; Emily E Graves; Vidyanand Shukla; Alexandros Makriyannis; Ben A Bahr Journal: Neurotherapeutics Date: 2012-10 Impact factor: 7.620
Authors: Tariq G Fellous; Andia N Redpath; Mackenzie M Fleischer; Sapan Gandhi; Samantha E Hartner; Michael D Newton; Moïra François; Suet-Ping Wong; Kate H C Gowers; Adam M Fahs; Daniel R Possley; Dominique Bonnet; Paula Urquhart; Anna Nicolaou; Kevin C Baker; Sara M Rankin Journal: NPJ Regen Med Date: 2020-02-21
Authors: Karen L G Farizatto; Sara A McEwan; Vinogran Naidoo; Spyros P Nikas; Vidyanand G Shukla; Michael F Almeida; Aaron Byrd; Heather Romine; David A Karanian; Alexandros Makriyannis; Ben A Bahr Journal: J Mol Neurosci Date: 2017-08-12 Impact factor: 3.444
Authors: Rishi Sharma; Spyros P Nikas; Carol A Paronis; Jodianne T Wood; Aneetha Halikhedkar; Jason Jianxin Guo; Ganesh A Thakur; Shashank Kulkarni; Othman Benchama; Jimit Girish Raghav; Roger S Gifford; Torbjörn U C Järbe; Jack Bergman; Alexandros Makriyannis Journal: J Med Chem Date: 2013-12-10 Impact factor: 7.446
Authors: Jodianne T Wood; John S Williams; Lakshmipathi Pandarinathan; David R Janero; Carol J Lammi-Keefe; Alexandros Makriyannis Journal: J Lipid Res Date: 2010-01-13 Impact factor: 5.922